PNC Financial Services Group Inc. Has $439,000 Position in Vaxcyte, Inc. (NASDAQ:PCVX)

PNC Financial Services Group Inc. grew its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVXFree Report) by 25.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,986 shares of the company’s stock after buying an additional 1,411 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Vaxcyte were worth $439,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Vaxcyte by 0.6% in the third quarter. Vanguard Group Inc. now owns 8,284,246 shares of the company’s stock valued at $422,331,000 after buying an additional 47,872 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Vaxcyte by 3.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock valued at $234,442,000 after acquiring an additional 167,501 shares during the period. Westfield Capital Management Co. LP bought a new position in shares of Vaxcyte in the 3rd quarter valued at about $51,180,000. Norges Bank acquired a new position in shares of Vaxcyte during the 4th quarter worth about $57,494,000. Finally, Northern Trust Corp raised its holdings in shares of Vaxcyte by 4.1% in the 3rd quarter. Northern Trust Corp now owns 896,635 shares of the company’s stock valued at $45,710,000 after purchasing an additional 35,694 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on PCVX shares. Needham & Company LLC reiterated a “buy” rating and set a $95.00 price target on shares of Vaxcyte in a report on Thursday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Thursday, May 9th.

Read Our Latest Stock Analysis on PCVX

Vaxcyte Stock Performance

NASDAQ PCVX opened at $72.24 on Tuesday. The stock has a market cap of $7.86 billion, a PE ratio of -16.88 and a beta of 0.94. The firm has a 50-day moving average of $66.10 and a 200-day moving average of $65.27. Vaxcyte, Inc. has a 52-week low of $44.20 and a 52-week high of $82.04.

Vaxcyte (NASDAQ:PCVXGet Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.28. As a group, analysts predict that Vaxcyte, Inc. will post -3.96 EPS for the current fiscal year.

Insider Activity at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $66.93, for a total transaction of $1,003,950.00. Following the transaction, the chief executive officer now owns 477,847 shares in the company, valued at approximately $31,982,299.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $69.02, for a total value of $552,160.00. Following the completion of the sale, the chief financial officer now directly owns 95,679 shares in the company, valued at $6,603,764.58. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $66.93, for a total value of $1,003,950.00. Following the sale, the chief executive officer now directly owns 477,847 shares in the company, valued at approximately $31,982,299.71. The disclosure for this sale can be found here. Insiders sold 69,000 shares of company stock worth $4,616,440 in the last ninety days. 3.10% of the stock is owned by company insiders.

Vaxcyte Company Profile

(Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

See Also

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVXFree Report).

Institutional Ownership by Quarter for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.